MINE Score Calculator for Canine Mitral Valve Disease
Grade myxomatous mitral valve disease from four routine echo measurements: LA/Ao, LVIDDn, fractional shortening and E-wave velocity. Each measurement is shown before you are asked for it.
For veterinary teams. The MINE score was built and tested in dogs of 20 kg (44.1 lb) or less with myxomatous mitral valve disease, not in atrial fibrillation, with a fractional shortening of 25% or more. It grades the echo. It does not replace ACVIM staging.
For veterinary professionals. The MINE score grades the echocardiographic severity of myxomatous mitral valve disease in dogs. It does not diagnose congestive heart failure, replace ACVIM staging or set treatment. Survival figures are medians from retrospective referral-hospital cohorts and are not a prediction for an individual dog. Check every measurement against the images before you report it.
How the MINE score works
Quick answer
The Mitral INsufficiency Echocardiographic (MINE) score adds points for four measurements: LA/Ao (1 to 4), LVIDDn (1 to 4), fractional shortening (1 to 3) and E-wave velocity (1 to 3). The total runs from 4 to 14. A total of 4 to 5 is mild, 6 to 7 moderate, 8 to 12 severe and 13 to 14 late stage. In the 560 dogs it was built on, median survival to cardiac death fell from 2344 days in mild disease to 157 days in late-stage disease.
Points for each measurement
| Measurement | 1 point | 2 points | 3 points | 4 points |
|---|---|---|---|---|
| LA/Ao | below 1.70 | 1.70 to 1.90 | 1.91 to 2.50 | above 2.50 |
| LVIDDn | below 1.70 | 1.70 to 2.00 | 2.01 to 2.30 | above 2.30 |
| FS (%) | below 45 | 45 to 50 | above 50 | not used |
| E-vel (m/s) | below 1.20 | 1.20 to 1.50 | above 1.50 | not used |
The 2021 paper prints the 3-point band for LVIDDn as 2.10 to 2.30, which leaves 2.01 to 2.09 unassigned. The 2025 follow-up from the same group states that the earlier cut-offs were kept and prints the band as 2.01 to 2.30. This calculator uses 2.01 to 2.30. LA/Ao, LVIDDn and E velocity are rounded to two decimal places, and fractional shortening to one, before they are scored, so the points always match the number shown. The papers do not say how values were rounded.
Severity classes and survival
| Class | Total | Dogs | Median survival (days) | 95% CI |
|---|---|---|---|---|
| Mild | 4 to 5 | 239 | 2344 | 1877 to 2810 |
| Moderate | 6 to 7 | 113 | 1882 | 1341 to 2434 |
| Severe | 8 to 12 | 186 | 623 | 432 to 710 |
| Late stage | 13 to 14 | 22 | 157 | 53 to 257 |
A total above 8 predicted cardiac death with a sensitivity of 87% and a specificity of 73% (area under the curve 0.85). All four measurements were independent predictors of cardiac death; E-wave velocity carried the largest hazard ratio (5.63 per m/s).
How it sits beside ACVIM staging
Dogs in the same ACVIM stage did not all share the same outlook. Splitting each stage by MINE class separated them.
| ACVIM stage | MINE class | Median survival (days) | 95% CI |
|---|---|---|---|
| B1 | Mild | 2344 | 1879 to 2808 |
| B1 | Moderate | 1882 | 1348 to 2416 |
| B2 | Moderate | 1644 | 1371 to 1784 |
| B2 | Severe | 1107 | 799 to 2192 |
| C or D | Severe | 388 | 264 to 469 |
| C or D | Late stage | 171 | 93 to 249 |
The paper's stage counts add up to 115 moderate, 185 severe and 21 late-stage dogs, against class totals of 113, 186 and 22. Both are shown as published.
MINE score 2 for preclinical dogs
A 2025 study of 749 dogs in stage B1 or B2 found that fractional shortening did not add to the prediction once LA/Ao, LVIDDn and E-wave velocity were known. MINE score 2 drops it. The three remaining measurements keep their points, the total runs from 3 to 11, and the endpoint is the first of congestive heart failure or cardiac death.
| Class | Total | Dogs | Median time to event (days) | 95% CI |
|---|---|---|---|---|
| Mild | 3 to 4 | 389 | 2604 | 2344 to 2604 |
| Moderate | 5 to 6 | 258 | 1216 | 998 to 1882 |
| Severe | 7 to 10 | 102 | 718 | 599 to 980 |
| Late stage | 11 | 0 | no dogs | no dogs |
Within stage B2, severe dogs reached a cardiac event at a median of 718 days against 1141 days for moderate dogs. The authors propose calling a B2 dog that scores severe on MINE score 2 advanced B2. Within stage B1 the difference between mild and moderate was not statistically significant.
ACVIM stage criteria used by the stage helper
| Stage | Definition | Monitoring stated in the consensus |
|---|---|---|
| B1 | Mitral regurgitation, never in heart failure, and not meeting all the B2 criteria | Re-evaluate in 6 to 12 months |
| B2 | Never in heart failure, with murmur grade 3 of 6 or louder, LA/Ao 1.6 or more, LVIDDn 1.7 or more and breed-adjusted vertebral heart score above 10.5. The consensus Table 1 lists the matching LVIDd for each kg rounded to 0.1 cm, so a dog just under LVIDDn 1.70 here can meet the criterion in that table. Re-measure a dog this close to the line. | 6 to 12 months (no fixed interval in the consensus) |
| C | Current or past signs of heart failure that respond to standard treatment | Kidney values and electrolytes 3 to 14 days after starting furosemide or an ACE inhibitor; resting respiratory rate at home |
| D | Heart failure refractory to standard treatment, needing 8 mg/kg of furosemide a day or more, or the torsemide equivalent | Kidney values 12 to 48 hours after a diuretic dose increase |
Mitral regurgitation severity index (MRSI)
When heart rate and age are entered, the calculator also reports the MRSI: heart rate divided by 120, times LA/Ao, times age in years divided by 10, times 100. In 869 dogs pooled from four earlier studies (234 of them stage B2, from three of the studies), a stage B2 dog with an MRSI above 156 reached congestive heart failure at a median of 407 days against 1404 days for dogs at or below it, and an MRSI above 173 predicted death from any cause (median 868 against 1843 days). It is a modest predictor on its own (AUC 0.68 and 0.64). The index did not predict outcome reliably in stage C, so the cut-offs are shown for B2 dogs only.
What the optional findings add
- Systolic blood pressure. A repeatable reading of 160 mmHg or more is hypertension. Higher afterload pushes more blood back through the valve.
- Tricuspid regurgitation velocity. The pressure gradient is 4 times the velocity squared. At 3.0 m/s or below pulmonary hypertension is unlikely on velocity alone, above 3.0 and up to 3.4 m/s is intermediate, and above 3.4 m/s it is likely when right heart changes are present.
- Flail leaflet or ruptured chordae. A sudden rise in regurgitation can outrun left atrial enlargement, so a modest score does not rule out a severe leak.
- Pericardial effusion. In a small dog with a very large left atrium, a left atrial tear has to be ruled out.
- Diuretic dose and timing. Left atrial size and E velocity both fall with diuresis. Two scans can only be compared if the treatment at each is known.
When the score does not apply
- Dogs over 20 kg (44.1 lb). Excluded from both studies. Larger dogs tend to progress faster, with more obvious myocardial dysfunction.
- Dogs under 3 years. Excluded so that congenital mitral valve disease was not counted.
- Fractional shortening under 25%. Excluded. A low FS with a volume-loaded ventricle is systolic failure, which the points table reads the wrong way round.
- Atrial fibrillation. Excluded. There is no A wave and every beat fills differently.
- Other cardiac or systemic disease. Excluded. Anything that raises preload or heart rate will move E velocity and FS.
- Pregnancy. Excluded from the 2021 study.
- Diuretics. Dogs on diuretics, or on heart drugs other than pimobendan, ACE inhibitors and spironolactone, were excluded from the MINE score 2 study.
- Cats. The score has not been studied in cats.
Common measurement mistakes
- Measuring the left atrium in mid-systole or at end-diastole. The size changes through the cycle; use the first frame after aortic valve closure every time.
- Letting the left atrial line run into the auricle or a pulmonary vein, which inflates the ratio.
- An oblique M-mode cut. An oval ventricle overstates LVIDd and understates FS.
- Typing LVIDd in millimeters into a field set to centimeters. The calculator checks for this.
- Reporting a fused E and A wave as E.
- Scoring a dog an hour after intravenous furosemide and comparing it with a scan taken before treatment. E velocity and left atrial size fall with diuresis.
Questions vets ask
Does the MINE score replace ACVIM staging?
No. ACVIM staging combines the murmur, history, radiographs and echo to decide treatment. The MINE score uses echo alone to grade severity and adds prognostic detail inside each stage. Report both.
What does a MINE score above 8 mean?
In the original cohort a total above 8 predicted death from heart disease with 87% sensitivity and 73% specificity. Dogs scoring 8 to 12 had a median survival to cardiac death of 623 days.
What is advanced B2?
A stage B2 dog whose MINE score 2 is 7 or more. These dogs reached congestive heart failure or cardiac death at a median of 718 days, against 1141 days for B2 dogs scoring 5 to 6. No dog in the 2025 study scored 11; the authors defined advanced B2 for a severe score (7 to 10), and this calculator also applies it to 11.
Why does a higher fractional shortening score more points?
With a leaking mitral valve the ventricle fills more and empties partly into the low-pressure left atrium, so it shortens more. A rising FS in a small dog with mitral regurgitation tracks a larger regurgitant volume, not a stronger heart.
How is LVIDDn calculated?
LVIDd in centimeters divided by body weight in kilograms raised to the power 0.294. A 3.3 cm ventricle in an 8 kg (17.6 lb) dog gives 3.3 divided by 1.84, which is 1.79.
References
- Vezzosi T, Grosso G, Tognetti R, Meucci V, Patata V, Marchesotti F, Domenech O. The Mitral INsufficiency Echocardiographic score: a severity classification of myxomatous mitral valve disease in dogs. J Vet Intern Med 2021;35(3):1238-1244. doi:10.1111/jvim.16131
- Vezzosi T, Grosso G, Vatne L, et al. Risk stratification using Mitral INsufficiency Echocardiographic score 2 in dogs with preclinical mitral valve disease. J Vet Intern Med 2025;39(5):e70215. doi:10.1111/jvim.70215
- Keene BW, Atkins CE, Bonagura JD, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med 2019;33(3):1127-1140. doi:10.1111/jvim.15488
- Cornell CC, Kittleson MD, Della Torre P, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004;18(3):311-321. doi:10.1892/0891-6640(2004)18<311:asomcm>2.0.co;2
- Hansson K, Häggström J, Kvart C, Lord P. Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in Cavalier King Charles Spaniels with and without left atrial enlargement. Vet Radiol Ultrasound 2002;43(6):568-575. doi:10.1111/j.1740-8261.2002.tb01051.x
- Thomas WP, Gaber CE, Jacobs GJ, et al. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. J Vet Intern Med 1993;7(4):247-252. doi:10.1111/j.1939-1676.1993.tb01015.x
- Vereb M, Atkins CE, Adin D, et al. Efficacy of a mitral regurgitation severity index to predict long-term outcome in dogs with myxomatous mitral valve disease. J Vet Intern Med 2024;38(1):51-60. doi:10.1111/jvim.16923
- Reinero C, Visser LC, Kellihan HB, et al. ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs. J Vet Intern Med 2020;34(2):549-573. doi:10.1111/jvim.15725
- Acierno MJ, Brown S, Coleman AE, et al. ACVIM consensus statement: guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med 2018;32(6):1803-1822. doi:10.1111/jvim.15331
- Ohad DG, Rishniw M, Ljungvall I, Porciello F, Häggström J. Sleeping and resting respiratory rates in dogs with subclinical heart disease. J Am Vet Med Assoc 2013;243(6):839-843. doi:10.2460/javma.243.6.839
Ask A Vet’s vet support lives in the app. See the app